Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q11203

UPID:
SIAT6_HUMAN

ALTERNATIVE NAMES:
Beta-galactoside alpha-2,3-sialyltransferase 3; Gal beta-1,3(4) GlcNAc alpha-2,3 sialyltransferase; N-acetyllactosaminide alpha-2,3-sialyltransferase; ST3Gal III; ST3N; Sialyltransferase 6

ALTERNATIVE UPACC:
Q11203; A9Z1W2; D3DPX8; Q5T4W9; Q5T4X0; Q5T4X7; Q5T4X8; Q5T4X9; Q5T4Y0; Q5T4Y2; Q5T4Y3; Q5T4Y4; Q86UR6; Q86UR7; Q86UR8; Q86UR9; Q86US0; Q86US1; Q86US2; Q8IX41; Q8IX42; Q8IX43; Q8IX44; Q8IX45; Q8IX46; Q8IX47; Q8IX48; Q8IX49; Q8IX50; Q8IX51; Q8IX52; Q8IX53; Q8IX54; Q8IX55; Q8IX56; Q8IX57; Q8IX58

BACKGROUND:
ST3Gal III, known for its role in catalyzing the formation of sialylated glycoconjugates, is essential for proper glycoprotein and glycolipid function. Its activity influences various biological processes, including cell adhesion and immune response modulation.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in Intellectual developmental disorder, autosomal recessive 12, and Developmental and epileptic encephalopathy 15, exploring ST3Gal III's function offers a promising avenue for developing targeted therapies for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.